Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis.

Department of Clinical Psychiatry and Psychotherapy, Medical School of Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
Acta Psychiatrica Scandinavica (Impact Factor: 5.55). 05/2004; 109(4):269-74. DOI: 10.1046/j.1600-0447.2003.00251.x
Source: PubMed

ABSTRACT The aim of this study was to further evaluate the oestrogen hypothesis of schizophrenia, which postulates low oestradiol levels to be a risk factor for these disorders. A possible influence of neuroleptic-induced hyperprolactinaemia was to be addressed.
Sex hormones were measured and cycle phase assessed in 50 acutely psychotic women on admission and for four consecutive weeks as well as in three control groups.
Psychotic women were more likely to be admitted during a low oestrogen phase of their cycle and exhibited markedly reduced oestradiol levels, compared with 23 healthy controls, as well as 50 women suffering from other psychiatric disorders. Oestradiol variability was reduced over the menstrual cycle in women suffering from psychotic disorders.
These results support the oestrogen hypothesis. Hyperprolactinaemia due to neuroleptic treatment does not appear to account for the findings.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Degenerative diseases of the central nervous system, the incidence and prevalence of which vary between men and women, often manifest in the hippocampus. Neurosteroids are hormones that are synthesized in the CNS, and it is here that they exert their influence. Estrogen and testosterone are examples of neurosteroid hormones. In the hippocampus, an area of the brain closely associated with learning and memory, the local synthesis of estrogen in females, but not in males, is essential for the plasticity and stability of the synapses. The inhibition of estrogen synthesis in the female hippocampus causes a reduction in long-term potentiation (LTP), an electrophysiological parameter of learning and memory, thus resulting in a significant loss of synapses. In light of this, the fact that estrogen has been attributed with many neuroprotective functions in degenerative diseases of the CNS suggests that therapeutic concepts involving the use of estrogen are possibly only effective in women, but not in men. These findings similarly provide a basis for explaining the gender dimorphism that has been found in certain degenerative illnesses of the CNS.
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 08/2014; 57(9). DOI:10.1007/s00103-014-2014-4 · 1.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To better understand premenstrual exacerbations of schizophrenia in women and weigh treatment options. Method: A PubMed literature search was conducted, using the search terms “schizophrenia”, “psychosis” “menstrual exacerbation”, “hormones” and assessing relevance to premenstrual exacerbation of schizophrenia symptoms. Results: Exacerbations are usually distinguishable from periodic or menstrual psychosis, a relatively rare condition. Controversy continues about whether low estrogen periods of the month lead to an increase in schizophrenia symptoms among women of reproductive age or whether some women suffer from both schizophrenia and premenstrual dysphoric disorder (PMDD). No treatment trials of specific interventions have been conducted so that physicians must decide on a case by case basis whether to raise antipsychotic doses premenstrually, try estrogens or estrogen/progesterone combinations or selective estrogen receptor modulators, or target PMDD symptoms. Conclusion: Clinicians need to be aware of premenstrual symptom aggravation in a large minority of women with schizophrenia. Treatment strategies will depend on the nature of the symptoms that are exacerbated. Optimal treatment needs to be adjusted to the individual woman.
    Acta Psychiatrica Scandinavica 05/2012; 125(5):363-371. DOI:10.1111/j.1600-0447.2011.01822.x · 5.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hippocampal volume (HV) decline is an important marker of psychosis and has been associated with hypothalamus-pituitary-adrenal (HPA) axis dysregulation in various disorders. Given recent findings of sex differences in HPA axis function in psychosis, the current study investigated differences in HV in male and female first episode psychosis (FEP) patients and controls and the interaction of HV with the cortisol awakening response (CAR) and symptoms. Fifty-eight patients with a diagnosis of FEP (39 men, 19 women) and 27 healthy community controls (15 men, 12 women) underwent structural magnetic resonance imaging (MRI) on a 1.5 T scanner. Hippocampal volume was determined using previously established segmentation protocols. Saliva samples for cortisol assessment were collected at 0, 30 and 60 min after awakening. Psychotic symptoms were assessed with the Scale for Assessment of Positive Symptoms (SAPS), the Scale for Assessment of Negative Symptoms (SANS) and the Global Assessment of Functioning (GAF) scale. Male patients had significantly smaller left and right HVs compared to male controls, which appeared to be secondary to global brain volume differences. However, even when controlling for overall brain size, male patients showed smaller HV compared to female patients. The CAR was significantly lower in male patients compared to male controls and female patients. Only in male patients, smaller left HV was significantly associated with a blunted CAR, and smaller HV bilaterally was related to positive psychotic symptoms and lower levels of functioning. We propose that reduced hippocampal volume and an attenuated cortisol awakening response are related markers of increased stress vulnerability in male psychosis patients and that both contribute to the unfavorable clinical picture in men.
    01/2015; 7:195-202. DOI:10.1016/j.nicl.2014.12.001